Session » Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Lupus Nephritis

Meeting: 2014 ACR/ARHP Annual Meeting

Abstract Number: 958

The 10-Year Followup of a Trial Comparing Azathioprine and Mycophenolate Mofetil for Long-term Immunosuppression of Lupus Nephritis

Abstract Number: 959

Discoid Lupus Onset and Decrease Risk of Renal Disease in Patients with Systemic Lupus Erythematosus: Data from a Large Latin American Cohort

Abstract Number: 960

Allogeneic Mesenchymal Stem Cell Transplantation for Lupus Nephritis Patients Refractory to Conventional Therapy

Abstract Number: 961

Outcome of Lupus Nephritis and Impact on Health Related Quality of Life: Results from an International, Prospective, Inception Cohort Study

Abstract Number: 962

A Systematic Review and Network Meta-Analysis of the Risk of Serious Infections with Immunosuppressives for Lupus Nephritis

Abstract Number: 963

Reduction in Proteinuria and Normalization of C4 Complement Levels Predict Response to Treatment of Lupus Nephritis with Low-Dose Pulse Cyclophosphamide and Abatacept

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.